Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2010 - 2026)

Pacira BioSciences' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $21.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 0.77% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $91.2 million (up 11.85% YoY), while the FY2025 annual figure was $91.0 million, up 15.53% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $21.3 million, roughly flat from $21.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $30.4 million in Q4 2022, with the low at $18.4 million in Q1 2024.
• The 5-year median for Depreciation & Amortization (CF) is $20.3 million (2024), against an average of $21.1 million.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 326.06% in 2022, then slumped 39.21% in 2023.
• Pacira BioSciences' Depreciation & Amortization (CF) stood at $30.4 million in 2022, then plunged by 39.21% to $18.5 million in 2023, then climbed by 14.92% to $21.2 million in 2024, then climbed by 0.47% to $21.3 million in 2025, then decreased by 0.05% to $21.3 million in 2026.
• Business Quant data shows PCRX's Depreciation & Amortization (CF) at $21.3 million in Q1 2026, $21.3 million in Q4 2025, and $21.2 million in Q3 2025.